SIGX1094: World’s First Organoid+AI-Developed Gastric Cancer Drug Receives FDA Fast Track Designation; Overview of 48 Domestic Organoid Companies
SIGNET
Innovative Targeted Cancer Drug Developer
Click the image to view the detailed schedule
February 18, 2025
eMedClub News
Recently, Signet Therapeutics (hereinafter referred to as "Signet") announced that the company's core pipelineSIGX1094Granted Fast Track Designation (FTD) by the U.S. FDA. This new designation follows the FDA Orphan Drug Designation (ODD) awarded to SIGX1094 in November 2024, and is expected to shorten its approval timeline and accelerate its market entry.
SIGX1094 is a SIGNET-based "Organoids + AI"The core candidate drug developed by the drug discovery platform, alsoThe World's FirstCandidate drugs developed by integrating organoid and AI technologies are mainly used for the treatment of diffuse gastric cancer and other advanced solid tumors.
Previously, SIGX1094 received IND approval from the U.S. FDA in June 2024 and China NMPA in September 2024. On December 26, 2024, SIGNET announced that SIGX1094 had administered the first dose to a patient at Peking University Cancer Hospital. The Phase 1 clinical trial is being led by Professor Lin Shen, an authoritative expert in the field of gastrointestinal tumors.
It is worth noting that this candidate drugFrom the discovery of a new target to the approval of the IND, it only tookMore than three yearsTime. SIGNET has entered into an in-depth collaboration with XtalPi, an AI-driven pharmaceutical company, to target the newly discovered therapeutic site, and within just6 MonthsDesigned and optimized a candidate compound with a novel molecular structure and superior comprehensive drug-like properties. Relying on its organoid disease model platform, the company conducted efficacy evaluations and tests to screen for molecules that closely mimic real patient responses.
As the first company in China to develop innovative targeted cancer drugs based on organoid disease models + AI,Within one year of its establishment, SIGNET completedThree rounds, totaling 150 million yuanAngel Round FinancingIn December 2024, Signet Therapeutics once again received more than70 million yuanThePre-A RoundFinancing and project funding to support the Phase 1 clinical trial of its first pipeline, SIGX1094, and the IND application for the second pipeline.
Not long after financing, SIGNET quickly partnered with the world’s first “3D-Wet-AI” biotech company that integrates organoid-on-a-chip, high-content three-dimensional (3D) cellular imaging, computer vision (CV), and artificial intelligence (AI) technologies for drug discovery.YaoSu TechnologyA heavyweight cooperation has been reached, aiming to integrate the strengths of both parties in organoid and organ-on-a-chip technologies to promote the industrialization process.
Fierce Competition in the Organoid Blue Ocean Surge
eMedClub
In the traditional new drug development model, the entire process from drug discovery to obtaining IND approval usually takes more than 5 to 10 years, accompanied by high costs and a high failure rate. "One drug, 10 years of work, over 2 billion dollars, with a success rate of less than 5%," whether for innovative pharmaceutical companies or large pharmaceutical enterprises,The Huge Risks and Enormous Investments in R&DAll are the eternal core propositions of innovative drugs.
Through organoid disease models and AI patterns, the human body environment can be simulated earlier, bridging preclinical models and clinical patients to the greatest extent. This innovative model not only accelerates the speed of new drug development and increases clinical success rates but also potentially reduces R&D costs by billions of dollars, marking a new era in drug development.The Convergence of Biology and Information Technology (BT and IT Convergence)Times.
Click the image to view the detailed schedule
From the perspective of the global organoid industry, although the entire industry is still in the early stages of development, the competition in this blue ocean track is fiercely surging. From the commercialization progress of organoids to the continuous increase in the scale of investment and financing cases,Johnson & Johnson, Merck, AstraZeneca, Pfizer, Sanofi, Bristol-Myers SquibbIncluding SIGNET and more than 20 multinational companiesProduct Purchase, Collaboration Authorization, and Investmentin forms such as directly entering the field.
In the fierce competition, enterprises that have core technology advantages and complete industrial chains in this field undoubtedly have a first-mover advantage. According to incomplete statistics, many companies in China have laid out plans in the organoid and organ-on-a-chip fields, coveringThe entire upstream, midstream, and downstream of the industry chain, including instruments and equipment, organoid and organ-on-a-chip technical services, pharmaceutical enterprises, and scientific research institutions. (Personally compiled; corrections and suggestions are welcome.)
▲ Organoid Companies in China
References:
1. SIGNET Official WeChat
2.https://mp.weixin.qq.com/s/6V2ux5HDLbREdKMFpC7Ssg
3.Other Public Information
Welcome everyone to register for the 2025 IBI EXPO conference and keep pace with the times.
Registration and Event Consultation
IBI EXPO 2025 (3rd) Biopharmaceutical Innovation Industry ConferenceWill beMarch 1, 2025 to March 2, 2025InSuzhou International Expo CenterGrandly held. The theme of the conference isCollaboratively Build the Entire Chain, Innovate and Transform the New Ecosystem。
The conference will invite300+Guest Speaker, Opening30+Field Forum Activities, Covering Hundreds of Hot Topics, Focusing onCell and Gene Therapy, Radiopharmaceuticals, Antibody Innovative Conjugation, Targeted Protein Degradation, Stem Cell Regeneration, mRNA Vaccines and Nucleic Acid Drugs, Exosomesetc.New Molecular Drugs,AI Drug Discovery, Organoids, Novel Delivery Vectorsetc.Frontier Technology，Engage in exchange and discussion, and collaboratePharmaceutical companies, research institutions, clinical resources, supply chain enterprises, investment and financing institutions, park governmentsWith the efforts of multiple parties, cutting-edge innovations are being transformed from scientific research to industrial applications, injecting a source of development into the biotech innovation drug market.
Free Participation:Teacher Yang 15517201185
Free Exhibition:Teacher Yuan 15572286596
Speech & Media：Teacher Wang 18717836231
Little Dot "Share”、“Like" and "In view", give me a little recharge~"